LY-367642
LY-367642 is a drug that was developed by Eli Lilly and Company. It is a serotonin reuptake inhibitor and 5-HT1A receptor agonist. The drug was developed for the treatment of depression and anxiety disorders, but it was never marketed.
History[edit]
LY-367642 was developed by the pharmaceutical company Eli Lilly and Company. The drug was designed to act as a serotonin reuptake inhibitor and 5-HT1A receptor agonist. These properties suggested that it could be effective in the treatment of depression and anxiety disorders. However, for reasons that are not publicly disclosed, the drug was never marketed.
Pharmacology[edit]
LY-367642 acts as a serotonin reuptake inhibitor, which means it increases the levels of serotonin in the brain by preventing its reabsorption into the presynaptic cell. This results in an increase in the extracellular concentration of serotonin and therefore an increase in serotonergic neurotransmission.
The drug is also a 5-HT1A receptor agonist. The 5-HT1A receptor is a subtype of the 5-HT receptor, which binds the neurotransmitter serotonin. As an agonist of this receptor, LY-367642 can stimulate it to produce a response.
Potential Uses[edit]
Due to its pharmacological properties, LY-367642 was developed for the treatment of depression and anxiety disorders. Depression is a common mental health disorder characterized by persistent feelings of sadness and a lack of interest in activities. Anxiety disorders are a group of mental health disorders characterized by significant feelings of anxiety and fear.
See Also[edit]
 | This medical article is a stub. You can help WikiMD by expanding the page. |
LY-367642[edit]
-
LY-367642 Structure
